Auro Laboratories Maintains Stable Credit Outlook Amid Capacity Expansion

Reader Takeaway: Capacity expands on capex; higher debt and margin pressure pose near-term risks.

Rating Details and Outlook

Acuite Ratings & Research has assigned a stable outlook to Auro Laboratories Limited's bank facilities. The long-term facilities received an 'ACUITE BB+; Stable' rating, while short-term facilities were rated 'ACUITE A4+'. The total outstanding facilities rated amount to ₹79.80 crore. This rating action coincides with the company’s ongoing significant capital expenditure.

This expansion is primarily geared towards increasing manufacturing capacity, with the latest block slated for commissioning by August 2025. Upon completion, the capacity is projected to rise to 2,100 MT per year from the current 1,260 MT. The company is also pursuing further capex for forward integration into formulation products like tablets.

Rationale and Challenges

The 'Stable' outlook acknowledges the promoters' experience and the company's track record. However, the rating also highlights key challenges: modest scale benefits post-capex, intensive working capital requirements, and susceptibility to raw material price volatility in the competitive Active Pharmaceutical Ingredient (API) sector. The immediate concern revolves around increased leverage due to debt-funded expansion.

Company and Market Context

Auro Laboratories has historically focused on building its presence in the API manufacturing space. The company has embarked on phased capital expenditure programs over the years to scale up its production capabilities. These expansions have often involved debt financing, reflecting a strategy to grow capacity and market reach. Peers like Divi's Laboratories operate at a significantly larger scale, while Laurus Labs has diversified into formulations and CDMO services.

Key Developments and Impacts

• Manufacturing capacity is set to increase substantially, enhancing production potential upon commissioning of the new block by August 2025.
• The company is diversifying into forward integration with plans to manufacture formulation products such as tablets.
• Financial leverage is expected to rise in the near to medium term due to the ongoing debt-funded capex.
• Profitability metrics, already showing a decline in FY2025, may face continued pressure from raw material costs and forex fluctuations.
• The company will need to closely manage its working capital and debt levels to mitigate financial risks.

Identified Risks

• Increased Leverage: The moderate financial risk profile is marked by increased gearing due to debt-funded capex. Metrics could remain under pressure, with a downward rating action triggered if gearing exceeds 2.00 times or Debt Service Coverage Ratio (DSCR) falls below 1.5 times.
• Execution Challenges: Scaling up operations substantially amidst current global and economic conditions may pose challenges.
• Profitability Volatility: Profitability remains susceptible to price volatility in raw materials and forex fluctuations.
• Working Capital: Intensive working capital operations and an elongated receivables cycle require careful management.

Comparison with Industry Peers

While Auro Laboratories is expanding its API capacity, its scale remains considerably smaller compared to major players like Divi's Laboratories. Competitors such as Laurus Labs and Granules India also operate in the API space, with Laurus Labs notably branching into formulations and CDMO services – a strategic direction Auro Laboratories is now exploring.

Key Financial Metrics FY2025

• FY2025 saw a PAT Margin of 9.48%, a decrease from 14.53% in FY2024.
• The Total Debt to Tangible Net Worth ratio increased to 1.05 times in FY2025 from 0.63 times in FY2024.
• PBDIT to Interest coverage declined to 3.75 times in FY2025, down from 16.55 times in FY2024.

Future Monitoring Points

• Monitor the successful commissioning of the new manufacturing block and its immediate impact on revenue and profitability.
• Track the progress and success of the forward integration capex into tablet manufacturing.
• Observe the company's ability to manage increased debt levels and optimize working capital cycles.
• Assess the recovery of operating income and profitability towards historical performance levels.